BioSpace News Archive

IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

Synthace Ltd, the company behind Antha, the cloud-based software platform for automating and improving the success rate of biological processes, and the Tecan Group announce a partnership to deepen the integration between Synthace’s Antha software and Tecan’s Te-Chrom™ automated chromatography system to unlock the full potential of miniaturized protein purification.

Harbour BioMed announced the appointment of Dr. Jon Wigginton M.D., to the company’s scientific advisory board.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X imaging procedure for point-of-care real-time fluorescence wound imaging for bacterial presence, location and load

Oncopeptides AB announces that the Company hosts a symposium at the EHA 25 Virtual Edition on June 13th, focusing on the “Challenges in Managing Patients with Myeloma”.

The European Investment Bank and BioNTech SE concluded a €100 million debt financing agreement to support the development of BNT162, the company’s COVID-19 vaccine programme.

Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, announced it has raised $63 million in a Series A2 financing from both existing and new investors.